<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of chronic pleural effusions in the neonate</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of chronic pleural effusions in the neonate</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of chronic pleural effusions in the neonate</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph B Philips III, MD, FAAP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas Prescott Atkinson, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard Martin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H22118746"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pleural effusion occurs as a result of an abnormal fluid collection within the pleural space. Once a pleural effusion has been diagnosed in the neonate, management decisions are based on the effusion's effect on the respiratory status of the patient, which is primarily based on the size of the effusion and the cause and chronicity of the condition.</p><p>The management of chronic neonatal pleural effusions will be reviewed here. The etiology, presentation, and acute management of neonatal pleural effusions are discussed separately. (See  <a class="medical medical_review" href="/d/html/88437.html" rel="external">"Approach to the neonate with pleural effusions"</a>.)</p><p class="headingAnchor" id="H777247962"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>The management of recurrent and chronic effusions is primarily dependent on the likelihood and rapidity of resolution when the underlying cause is treated. Most cases of neonatal pleural effusions are transient and do not need further intervention. The following is our approach to managing a neonate following the initial acute management, which is discussed separately. (See  <a class="medical medical_review" href="/d/html/88437.html" rel="external">"Approach to the neonate with pleural effusions", section on 'Initial acute management'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who continue to be symptomatic, needle aspiration is repeated two or three times until it is clear that the effusion(s) will either clear or continue. In general, recurrent effusions caused by hydrops or other nonchylous etiologies can usually be treated with serial needle aspirations over a relatively brief period of time as the underlying condition is treated or spontaneously resolves.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with chronic effusions, defined as those requiring repeated needle aspirations to relieve respiratory distress, we place a chest tube for slow continuous drainage of fluid using an underwater seal system. In our center, we typically use pigtail catheters of 8.5 French or greater. We monitor chest tube output and serum electrolytes frequently and replace volume and adjust electrolyte infusions based on the composition and volume of the drainage. After initial chest radiographs confirm appropriate chest tube placement, they are repeated only if there is increased respiratory distress or if a sudden decrease in output occurs. (See <a class="local">'Tube thoracostomy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants with continued <strong>non-chylous</strong> drainage (transudate) primarily have fluid and electrolyte losses. In these infants, hydration and electrolyte status are monitored at least daily. Volume losses greater than approximately 6 mL/kg per hour are replaced with normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> and appropriate amounts of potassium, depending on the composition of the drainage, over an hour or two, every six to twelve hours. For infants with significant ongoing protein losses, the use of protein-containing replacement fluid should be considered so that the patient does not become hypo-proteinemic (eg, fresh frozen plasma instead of normal saline). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chylous</strong> pleural effusions are the most frequent cause of chronic neonatal pleural effusions. They are associated with continued and persistent accumulation of large volumes of pleural fluid. Prolonged drainage of chylothorax may lead to significant losses of fluid, electrolytes, proteins (including immunoglobulins), and lymphocytes. Depletion of immunoglobulins and lymphocytes may cause clinically significant immunosuppression. Because of the complexity of management of infants requiring prolonged drainage, we recommend transfer of such infants to tertiary centers with staff who have expertise in the care of these infants. </p><p></p><p class="headingAnchor" id="H2212532641"><span class="h2">Management approach for chylous effusion</span><span class="headingEndMark"> — </span>For neonates with chronic chylothorax, we use the following step-wise management approach:</p><p class="bulletIndent1"><span class="glyph">●</span>Our initial intervention is the use of a formula with a high concentration of medium-chain triglycerides. If drainage of chyle continues for more than a week, a trial of total parenteral nutrition (TPN) and nothing by mouth is administered. However, if possible, we prefer to continue enteral feeds due to the long-term complications of TPN. (See <a class="local">'Dietary management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For infants who fail to respond within one to two weeks of dietary measures with continued chest tube output, <a class="drug drug_pediatric" data-topicid="12655" href="/d/drug information/12655.html" rel="external">octreotide</a> is offered after discussion with the parent(s) or legal guardian of the infant regarding the risk and uncertainty of benefits. Of note, other centers do not use octreotide due to concern for adverse effects and data that report limited benefit. However, for infants with prolonged chest tube drainage despite dietary measures, we provide octreotide with parenteral at an initial dose of 1 mcg/kg per hour and increased by 1 mcg/kg per hour per day until a response is noted or the infusion rate reaches a maximum of 10 mcg/kg per hour. A positive response is considered to be at least a 25 percent reduction in output. Once a response is obtained, we usually continue infusion at the same rate for 7 to 10 days before beginning a slow taper over another week. If chest tube drainage increases, we increase the octreotide infusion rate and maintain it for at least another week before tapering and discontinuation. (See <a class="local">'Pharmacologic management'</a> below.)</p><p></p><p class="bulletIndent1">If maximal <a class="drug drug_pediatric" data-topicid="12655" href="/d/drug information/12655.html" rel="external">octreotide</a> dosing does reduce chest tube output after two or three days, we rapidly taper octreotide over a day or two and consider chemical pleurodesis or surgical intervention.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with chylothorax and prolonged drainage, serum albumin and clotting studies are measured once or twice weekly, and replacement therapy is administered as needed. Intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) therapy is considered for patients with hypoimmunoglobulinemia due to severe and prolonged loss. (See <a class="local">'Protein loss'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When the drainage has ceased, we remove the tubes and wait at least a week (and often longer) before starting to feed mother or donor human milk to the infant. If human milk is not available, a standard formula is provided. We continue to monitor the patient for another week or more for recurrence of a pleural effusion.</p><p></p><p class="headingAnchor" id="H777250091"><span class="h1">INTERVENTIONS</span></p><p class="headingAnchor" id="H22118767"><span class="h2">Tube thoracostomy</span><span class="headingEndMark"> — </span>In the neonate with persistent pleural effusion(s) that continue to cause respiratory distress despite serial needle aspirations, placement of a chest tube(s) with underwater seal system can slowly drain pleural fluid on an ongoing basis, resulting in improved respiratory function [<a href="#rid1">1</a>]. In neonates, chest tubes in a size range of 10 to 12 French, or pigtail catheters of 8.5 French or greater should be used. We prefer pigtail catheters as they seem to remain in place longer. </p><p>Similar to the insertion site used for needle aspiration, the tube should be inserted under sterile conditions with the infant in the supine position in the midaxillary line in the 5<sup>th</sup> or 6<sup>th</sup> intercostal space and directed posteriorly. The tube should be sutured in place and covered with an airtight occlusive dressing. The distal end is then connected to a closed system calibrated suction device with 10 to 15 cm water negative pressure. Proper position of the tube should be verified with a chest radiograph. Initially, the volume of drainage should be measured every six to eight hours after the initial volume has been drained. As the volume decreases, the measurement interval can be increased. Bilateral chest tube placement may be necessary if the effusions are large on both sides.</p><p>Continued drainage of pleural fluid either by repeated aspiration or chest tube drainage can lead to significant loss of fluid and electrolytes. (See <a class="local">'Volume and electrolyte loss management'</a> below.) </p><p>For chylous effusion, chronic drainage can lead to depletion of serum proteins, especially albumin and immunoglobulins, and lymphocytes. (See <a class="local">'Chylous effusions'</a> below.)</p><p>In neonates, persistent effusions are rarely due to infectious causes. The management of pediatric parapneumonic effusions and empyema, including the indications for chest tube placement, are discussed separately. (See  <a class="medical medical_review" href="/d/html/6345.html" rel="external">"Management and prognosis of parapneumonic effusion and empyema in children", section on 'Chest tubes'</a>.)</p><p class="headingAnchor" id="H22118774"><span class="h3">Volume and electrolyte loss management</span><span class="headingEndMark"> — </span>Significant volume and electrolyte loss can occur with chronic chest tube drainage. The electrolyte content of pleural effusions is similar to that of plasma. Thus, large amounts of water and electrolytes (especially sodium) can be lost with ongoing drainage. Daily assessments of weight and electrolytes are therefore essential in the early management of continuous chest tube output. The need for replacement of losses will depend on the magnitude of the losses and changes in serum electrolytes. The decision to replace lost volume depends on the infant's daily fluid and electrolyte intake. Volume loss should be calculated every 8 to 12 hours and, if greater than 6 mL/kg per hour, replacement with normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> or other appropriate solution should be given intravenously over one to two hours, every six to twelve hours. </p><p class="headingAnchor" id="H2806182636"><span class="h3">Protein loss</span><span class="headingEndMark"> — </span>In some cases, protein loss may also be significant depending on the composition of the pleural fluid. Analysis of the fluid will provide the protein concentration and will guide whether serum albumin levels should be monitored and if (when) protein replacement therapy (eg, fresh frozen plasma) is needed. </p><p class="headingAnchor" id="H22118837"><span class="h2">Pleurodesis</span><span class="headingEndMark"> — </span>Pleurodesis is a procedure that obliterates the pleural space to prevent a recurrent pleural effusion following pleural drainage. After draining the effusion, a chemical irritant that induces inflammation and fibrosis is instilled into the pleural space (ie, chemical pleurodesis). Various agents have been used for chemical pleurodesis. Many of these, especially chemotherapeutic agents, are contraindicated in neonates and young infants because of potential toxicities. (See  <a class="medical medical_review" href="/d/html/6695.html" rel="external">"Chemical pleurodesis for the prevention of recurrent pleural effusion"</a>.)</p><p>Data are limited in infants and include case reports, primarily in patients with persistent chylous effusions, using the following agents:</p><p class="bulletIndent1"><span class="glyph">●</span>Talc [<a href="#rid2">2</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Iodopovidone [<a href="#rid3">3-6</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12830" href="/d/drug information/12830.html" rel="external">Tetracycline</a> derivatives (<a class="drug drug_pediatric" data-topicid="13255" href="/d/drug information/13255.html" rel="external">doxycycline</a>) [<a href="#rid5">5,7</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Fibrin glue [<a href="#rid8">8-14</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><em>Streptococcus pyogenes</em> A3 (OK-432) [<a href="#rid15">15,16</a>]</p><p></p><p>The use of these agents need further study to determine efficacy and safety in the treatment of neonatal pleural effusions. As a result, these interventions cannot be recommended for routine use.</p><p>Nevertheless, an infant with persistent unilateral chylous effusion was successfully managed with pleurodesis using <a class="drug drug_pediatric" data-topicid="13255" href="/d/drug information/13255.html" rel="external">doxycycline</a> at our center. The decision to use pleurodesis should be made by knowledgeable clinicians on a case-by-case basis. </p><p class="headingAnchor" id="H22118886"><span class="h2">Surgical management</span><span class="headingEndMark"> — </span>Infants who continue to have chronic pleural effusions despite all attempts at medical therapy may require surgical intervention. Discussion of these options, which include mechanical pleurodesis, pleuroperitoneal shunt [<a href="#rid17">17-19</a>], and ligation of the thoracic duct [<a href="#rid13">13,14,20-22</a>], is beyond the scope of this review.</p><p class="headingAnchor" id="H777249746"><span class="h1">CHYLOUS EFFUSIONS</span></p><p class="headingAnchor" id="H119235692"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Management of infants with chylous effusions is challenging, as there are significant losses from pleural fluid drainage of fluid and electrolytes; proteins including albumin, clotting factors, and immunoglobulins; and, in addition to humoral components, cellular elements of immunity, particularly lymphocytes [<a href="#rid23">23,24</a>]. However, based on retrospective data from large case series, comprehensive management with ventilatory support, and dietary management focused on decreasing thoracic duct lymph flow (parenteral nutrition and the use of medium-chain triglycerides [MCT]) have improved the outcome of neonates with chylothorax [<a href="#rid25">25,26</a>]. </p><p class="headingAnchor" id="H1320847798"><span class="h2">Replacement therapy</span></p><p class="headingAnchor" id="H777249753"><span class="h3">Protein loss</span><span class="headingEndMark"> — </span>Because chyle contains significant amounts of protein, ongoing drainage can lead to significant loss of:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Albumin</strong> – Serum albumin concentrations should be followed once or twice weekly, and replacement should be given to maintain levels above 2 to 2.5 g/dL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coagulation factors</strong> – Coagulation factors, especially fibrinogen and factor VII, can be lost in clinically significant amounts. Periodic clotting studies should be obtained and fresh frozen plasma given as needed to normalize the values. Although there are no specific guidelines, we provide replacement therapy to maintain coagulation studies at a threshold of no less than 1.5 times normal values.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunoglobulin</strong> – Although there are no published guidelines regarding the management of immunoglobulin loss, there is a significant loss of immunoglobulins with ongoing chyle drainage, which may result in severe hypoimmunoglobulinemia [<a href="#rid27">27-29</a>]. Older studies in animals have demonstrated that thoracic duct cannulation and drainage for as little as five days can produce a significant humoral and cellular immune defect [<a href="#rid30">30</a>]. As a result, we monitor serum immunoglobulin G (IgG) levels on a weekly basis and begin replacement dosing with intravenous immunoglobulin (<a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">IVIG</a>) to maintain a targeted trough level of 500 mg/dL, which is the mean IgG level for a one-month-old infant and the replacement trough level used in the care of patients with primary immune deficiencies [<a href="#rid31">31</a>]. Initial dosing of IVIG for immune replacement is 400 to 600 mg/kg. The normal half-life of IgG is approximately three weeks; however, with high rates of drainage, the replacement dose and interval will need to be adjusted to maintain the IgG level at or above the target level. (See  <a class="medical medical_review" href="/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity", section on 'Trough levels'</a>.)</p><p></p><p class="headingAnchor" id="H777249781"><span class="h3">Lymphocyte depletion</span><span class="headingEndMark"> — </span>Profound cellular deficiency occurs with prolonged chylous drainage, based on data from patients undergoing organ transplantation for whom 14 days of chylous drainage resulted in lymphocyte depletion to a degree associated with clinically significant immunosuppression. In order to avoid significant lymphocyte depletion, measures to reduce chyle production (eg, dietary measures) are initiated in patients who require chronic drainage. (See <a class="local">'Reduction of chyle drainage'</a> below.)</p><p>The potential complications of such lymphocyte depletion were illustrated in a large case series of 178 infants with chylous effusions, among whom a low absolute lymphocyte count was associated with culture-positive sepsis [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H862330013"><span class="h2">Reduction of chyle drainage</span></p><p class="headingAnchor" id="H777249795"><span class="h3">Dietary management</span><span class="headingEndMark"> — </span>Dietary management is focused on decreasing thoracic duct lymph flow and includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The use of formula with a high concentration of MCT and a low concentration of long-chain fatty acids has been shown to be effective in decreasing chyle flow with resolution of chylous effusions [<a href="#rid20">20,21,26,32,33</a>]. Fat-free human milk produced by centrifugation and supplemented with MCT or total parenteral nutrition (TPN) has also been reported to be successful in the management of both congenital and postoperative chylothorax [<a href="#rid34">34</a>]. The mechanism of decreased chyle flow appears to be due to MCT being directly absorbed into the portal vein system, thereby bypassing the lymphatic system and resulting in a reduction in the volume and lipid concentration of the pleural fluid [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because enteral feeds stimulate thoracic duct lymph flow, withholding feeds (nothing by mouth) with administration of TPN decreases chylous flow. The regimen of nothing by mouth/TPN decreased chyle flow in patients who failed to respond to MCT [<a href="#rid21">21,32</a>].</p><p></p><p>Although the optimal approach is controversial, most centers, including our own, advocate an initial noninvasive trial of MCT-enriched formula, as most patients will respond with a decrease in chyle flow/drainage (defined as a 25 percent reduction in drainage) and resolution of the effusion, and TPN is associated with significant complications including cholestasis and central line infections. However, nothing by mouth/TPN is initiated for patients who fail to respond with an adequate decrease in drainage with MCT-enriched formula [<a href="#rid21">21,36</a>].</p><p>For infants responsive to dietary measures, the chest tube(s) are removed after the drainage ceases. Feeds with human milk are initiated in one to two weeks. If human milk is not available, standard formula is used.</p><p class="headingAnchor" id="H777249802"><span class="h3">Pharmacologic management</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12655" href="/d/drug information/12655.html" rel="external">Octreotide</a> is a synthetic analogue of somatostatin, a regulatory hormone that reduces intestinal blood flow and can decrease the production rate of chyle (see  <a class="medical medical_review" href="/d/html/2579.html" rel="external">"Physiology of somatostatin and its analogues"</a>). Octreotide has been reported to be beneficial in the treatment of chronic chylothorax in adults. However, we do not routinely use octreotide in neonates with chylothorax because it has significant adverse effects and data remain uncertain about whether it is beneficial in the management of chronic neonatal chylothorax. (See  <a class="medical medical_review" href="/d/html/16356.html" rel="external">"Management of chylothorax", section on 'Adjunctive therapies'</a>.)</p><p>We reserve the use of <a class="drug drug_pediatric" data-topicid="12655" href="/d/drug information/12655.html" rel="external">octreotide</a> for refractory cases of chronic neonatal chylothorax after a thorough discussion with the parent/caregiver of the infant regarding the uncertainty of risk and benefits. If given, octreotide can be administered either subcutaneously or intravenously. We prefer a continuous intravenous infusion starting at 1 mcg/kg per hour and increasing the dose once daily to a maximum of 10 mcg/kg per hour depending on the patient's response. Because octreotide blunts insulin release, close monitoring of serum glucose values should be performed during the induction phase with spacing of measurements as a stable infusion rate is achieved. If intravenous access is lost, octreotide can be given subcutaneously at the same dose at six- to eight-hour intervals until intravenous access is restored.</p><p>Adverse effects of <a class="drug drug_pediatric" data-topicid="12655" href="/d/drug information/12655.html" rel="external">octreotide</a> have been reported in approximately 14 percent of neonates treated for chylothorax [<a href="#rid37">37</a>]. Reported significant complications of octreotide for patients with chylothorax and other conditions (eg, congenital hyperinsulinism and enterocutaneous fistulas) include persistent pulmonary hypertension of the newborn (PPHN) and necrotizing enterocolitis (NEC) [<a href="#rid38">38-43</a>].</p><p>Data are uncertain about whether <a class="drug drug_pediatric" data-topicid="12655" href="/d/drug information/12655.html" rel="external">octreotide</a> is beneficial in the management of chronic neonatal chylothorax that is resistant to dietary management. In neonates, there are no clinical trials studying the effect of octreotide in the treatment of chylothorax. Evidence is limited to case reports, and data from observational studies are contradictory. A systematic review of 753 infants with congenital chylothorax reported that of the 138 infants treated with octreotide, approximately 78 percent had resolution of chylothorax without the need for surgical intervention [<a href="#rid44">44</a>]. An earlier systematic review reported that octreotide is a safe and relatively effective intervention with decrease or cessation of chylous drainage in approximately 50 percent of cases [<a href="#rid37">37</a>]. </p><p>In a large case series of 178 infants with chylous effusions that was not included in either review, 172 were initially managed medically with chest tube drainage and nutritional measures (eg, MCT enteral feeding, total parental feeds, and withholding of feeds) and 6 patients received no treatment [<a href="#rid26">26</a>]. Additional interventions included pharmacologic treatment with <a class="drug drug_pediatric" data-topicid="12655" href="/d/drug information/12655.html" rel="external">octreotide</a> for 45 patients and surgery for 21 patients. In this cohort, the administration of octreotide was not associated with additional benefit over dietary measures. In contrast, a small case series reported octreotide was safe and effective in treating refractory chylothorax in patients following surgery for congenital heart disease [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H777250204"><span class="h3">Other interventions</span><span class="headingEndMark"> — </span>Other interventions that have been used in neonates with chylothorax include the following; however, these interventions should not be used routinely, as the evidence of demonstrated benefit is inadequate. They should only be considered on a case-by-case basis for neonates that fail to respond to routine management.</p><p class="bulletIndent1"><span class="glyph">●</span>High-frequency ventilation and high end-expiratory pressure in patients on mechanical ventilation – In patients who are mechanically ventilated, high-frequency ventilation [<a href="#rid46">46</a>] and high end-expiratory pressure [<a href="#rid47">47</a>] have been reported to be beneficial in the management of infants with chylothorax.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="106992" href="/d/drug information/106992.html" rel="external">Inhaled nitric oxide</a> – A single case report noted a reduction in chyle flow with inhaled nitric oxide (iNO) in an infant with postoperative chylothorax and pulmonary hypertension [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Etilefrine – A report of two cases noted a significant reduction of chyle output after starting treatment with continuous infusion of etilefrine, a sympathomimetic agent with both alpha and beta adrenergic stimulation [<a href="#rid49">49</a>]. Both heart rate and blood pressure increased during the infusion but returned to basal values after etilefrine was discontinued.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids – There are also reports that glucocorticoid therapy may be helpful in the management of postoperative chylothorax [<a href="#rid50">50,51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12744" href="/d/drug information/12744.html" rel="external">Propranolol</a> – A limited number of reports suggest that propranolol may be effective in treating chylothorax [<a href="#rid52">52-55</a>]. Evidence is insufficient to recommend its use. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13000" href="/d/drug information/13000.html" rel="external">Sildenafil</a> – A single case report indicated successful treatment of an octreotide-resistant congenital chylothorax with the phosphodiesterase inhibitor sildenafil [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interventional cardiac catheterization – Chylothorax resulting from occlusion or stenosis of the left innominate vein may be successfully remedied by balloon dilation in the cardiac catheterization laboratory [<a href="#rid57">57</a>].</p><p></p><p class="headingAnchor" id="H29308628"><span class="h2">Follow-up management</span><span class="headingEndMark"> — </span>After resolution of chylothorax, long-term immunologic follow-up of patients depends on how rapidly T cell lymphocyte and immunoglobulin levels recover. Retrospective data from small cases series have failed to establish the beneficial effects of intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) for patients with chylothorax and hypoimmunoglobulinemia [<a href="#rid27">27-29,58</a>]. Nevertheless, we continue to provide IVIG to patients with persistent T cell lymphopenia and hypoimmunoglobulinemia until there is more definitive evidence of the lack of efficacy.</p><p>For patients who have recovery of T cell lymphocytes and immunoglobulins to normal or near normal concentrations by the time of discharge, no further follow-up is necessary beyond the usual discharge management based on the patient's neonatal intensive care hospitalization. (See  <a class="medical medical_review" href="/d/html/4974.html" rel="external">"Discharge planning for high-risk newborns"</a> and  <a class="medical medical_review" href="/d/html/5005.html" rel="external">"Care of the neonatal intensive care unit graduate"</a>.)</p><p class="headingAnchor" id="H115514162"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management of chronic pleural effusions in the neonate</strong> – Chronic pleural effusions are defined as those that require repeated needle aspirations to relieve respiratory distress. In neonates with chronic pleural effusions, we suggest chest tube placement for slow continuous drainage of fluid using an underwater seal system (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Losses associated with ongoing drainage</strong> – These include significant losses of water and electrolytes, and depending on the composition of the fluid, protein. As a result, daily assessments of weight and electrolytes are needed to determine the need of fluid replacement, including determination of volume and content. (See <a class="local">'Our approach'</a> above and <a class="local">'Tube thoracostomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of chylothorax drainage</strong> – Chylous drainage can persist over a considerable time period and be associated with significant losses of fluid, electrolytes, protein including albumin, clotting factors and immunoglobulins, and cellular elements of immunity, particularly lymphocytes. We manage these losses by replacement and by using measures to reduce chyle drainage (see <a class="local">'Protein loss'</a> above and <a class="local">'Lymphocyte depletion'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Replacing losses</strong> – We replace fluid and electrolyte losses depending on the magnitude of the losses and changes in serum electrolytes. (See <a class="local">'Volume and electrolyte loss management'</a> above.) </p><p></p><p class="bulletIndent2">We replace protein losses as follows (see <a class="local">'Protein loss'</a> above): </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Albumin</strong> – We suggest administering intravenous infusions of albumin to maintain serum albumin concentrations above 2 to 2.5 g/dL (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Clotting factors</strong> – We suggest administering an intravenous infusion of fresh frozen plasma to correct abnormal clotting studies to below 1.5 times the upper limit of normal (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Immunoglobulins</strong> – For patients with severe hypoimmunoglobulinemia, we suggest administering intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) to maintain a threshold level of immunoglobulin of 500 mg/dL. (See <a class="local">'Follow-up management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reducing chyle drainage</strong> – In patients with chronic chylothorax, we use a step-wise approach to reduce chyle flow (see <a class="local">'Our approach'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dietary management</strong> – We suggest an initial trial of formula with a high concentration of medium-chain triglycerides (MCT) and a low concentration of long-chain fatty acids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Dietary management'</a> above.)</p><p></p><p class="bulletIndent3">In patients who fail to respond to MCT-enriched formula, we suggest stopping oral feeds (nothing by mouth) and administering total parental nutrition (TPN) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Dietary management'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pharmacologic management not routinely used </strong>– We suggest not routinely using <a class="drug drug_pediatric" data-topicid="12655" href="/d/drug information/12655.html" rel="external">octreotide</a> for neonates with chronic chylothorax (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). In our center, octreotide is reserved on a case-by-case basis for patients who fail to respond to dietary measures. Data remain uncertain on its benefits in neonates. (See <a class="local">'Pharmacologic management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measures not routinely used </strong>– We do not routinely use the following measures to treat persistent neonatal pleural effusions: chemical pleurodesis and surgical interventions (ie, mechanical pleurodesis, pleuroperitoneal shunt, ligation of the thoracic duct for patients with chylothorax). However, infants who continue to have chronic effusions despite all attempts at medical therapy may require surgical intervention. (See <a class="local">'Pleurodesis'</a> above and <a class="local">'Surgical management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Margau R, Amaral JG, Chait PG, Cohen J. Percutaneous thoracic drainage in neonates: catheter drainage versus treatment with aspiration alone. Radiology 2006; 241:223.</a></li><li><a class="nounderline abstract_t">Graham DD, McGahren ED, Tribble CG, et al. Use of video-assisted thoracic surgery in the treatment of chylothorax. Ann Thorac Surg 1994; 57:1507.</a></li><li><a class="nounderline abstract_t">Brissaud O, Desfrere L, Mohsen R, et al. Congenital idiopathic chylothorax in neonates: chemical pleurodesis with povidone-iodine (Betadine). Arch Dis Child Fetal Neonatal Ed 2003; 88:F531.</a></li><li><a class="nounderline abstract_t">Murki S, Faheemuddin M, Gaddam P. Congenital chylothorax--successful management with chemical pleurodesis. Indian J Pediatr 2010; 77:332.</a></li><li><a class="nounderline abstract_t">Mitanchez D, Walter-Nicolet E, Salomon R, et al. Congenital chylothorax: what is the best strategy? Arch Dis Child Fetal Neonatal Ed 2006; 91:F153.</a></li><li><a class="nounderline abstract_t">Scottoni F, Fusaro F, Conforti A, et al. Pleurodesis with povidone-iodine for refractory chylothorax in newborns: Personal experience and literature review. J Pediatr Surg 2015; 50:1722.</a></li><li><a class="nounderline abstract_t">Hoff DS, Gremmels DB, Hall KM, et al. Dosage and effectiveness of intrapleural doxycycline for pediatric postcardiotomy pleural effusions. Pharmacotherapy 2007; 27:995.</a></li><li><a class="nounderline abstract_t">Sarkar S, Hussain N, Herson V. Fibrin glue for persistent pneumothorax in neonates. J Perinatol 2003; 23:82.</a></li><li><a class="nounderline abstract_t">Mathur NB, Singh B, Kumar A, Aggarwal SK. Successful treatment of congenital chylothorax using fibrin glue. Indian J Pediatr 2009; 76:758.</a></li><li><a class="nounderline abstract_t">Rifai N, Sfeir R, Rakza T, et al. Successful management of severe chylothorax with argon plasma fulguration and fibrin glue in a premature infant. Eur J Pediatr Surg 2003; 13:324.</a></li><li><a class="nounderline abstract_t">Nguyen D, Tchervenkov CI. Successful management of postoperative chylothorax with fibrin glue in a premature neonate. Can J Surg 1994; 37:158.</a></li><li><a class="nounderline abstract_t">Stenzl W, Rigler B, Tscheliessnigg KH, et al. Treatment of postsurgical chylothorax with fibrin glue. Thorac Cardiovasc Surg 1983; 31:35.</a></li><li><a class="nounderline abstract_t">Cleveland K, Zook D, Harvey K, Woods RK. Massive chylothorax in small babies. J Pediatr Surg 2009; 44:546.</a></li><li><a class="nounderline abstract_t">Pinto E, Dori Y, Smith C, et al. Neonatal lymphatic flow disorders: impact of lymphatic imaging and interventions on outcomes. J Perinatol 2021; 41:494.</a></li><li><a class="nounderline abstract_t">Matsukuma E, Aoki Y, Sakai M, et al. Treatment with OK-432 for persistent congenital chylothorax in newborn infants resistant to octreotide. J Pediatr Surg 2009; 44:e37.</a></li><li><a class="nounderline abstract_t">Kamiyama M, Usui N, Tani G, et al. Postoperative chylothorax in congenital diaphragmatic hernia. Eur J Pediatr Surg 2010; 20:391.</a></li><li><a class="nounderline abstract_t">Vasu V, Ude C, Shah V, et al. Novel surgical technique for insertion of pleuroperitoneal shunts for bilateral chylous effusions in Ex preterm infant at term corrected age. Pediatr Pulmonol 2010; 45:840.</a></li><li><a class="nounderline abstract_t">Engum SA, Rescorla FJ, West KW, et al. The use of pleuroperitoneal shunts in the management of persistent chylothorax in infants. J Pediatr Surg 1999; 34:286.</a></li><li><a class="nounderline abstract_t">Rheuban KS, Kron IL, Carpenter MA, et al. Pleuroperitoneal shunts for refractory chylothorax after operation for congenital heart disease. Ann Thorac Surg 1992; 53:85.</a></li><li><a class="nounderline abstract_t">Biewer ES, Zürn C, Arnold R, et al. Chylothorax after surgery on congenital heart disease in newborns and infants -risk factors and efficacy of MCT-diet. J Cardiothorac Surg 2010; 5:127.</a></li><li><a class="nounderline abstract_t">Beghetti M, La Scala G, Belli D, et al. Etiology and management of pediatric chylothorax. J Pediatr 2000; 136:653.</a></li><li><a class="nounderline abstract_t">Chan SY, Lau W, Wong WH, et al. Chylothorax in children after congenital heart surgery. Ann Thorac Surg 2006; 82:1650.</a></li><li><a class="nounderline abstract_t">Starzl TE, Koep LJ, Weil R 3rd, et al. Thoracic duct drainage in organ transplantation: will it permit better immunosuppression? Transplant Proc 1979; 11:276.</a></li><li><a class="nounderline abstract_t">GOWANS JL. The recirculation of lymphocytes from blood to lymph in the rat. J Physiol 1959; 146:54.</a></li><li><a class="nounderline abstract_t">Bialkowski A, Poets CF, Franz AR, Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland Study Group. Congenital chylothorax: a prospective nationwide epidemiological study in Germany. Arch Dis Child Fetal Neonatal Ed 2015; 100:F169.</a></li><li><a class="nounderline abstract_t">Church JT, Antunez AG, Dean A, et al. Evidence-based management of chylothorax in infants. J Pediatr Surg 2017; 52:907.</a></li><li><a class="nounderline abstract_t">Mohan H, Paes ML, Haynes S. Use of intravenous immunoglobulins as an adjunct in the conservative management of chylothorax. Paediatr Anaesth 1999; 9:89.</a></li><li><a class="nounderline abstract_t">Orange JS, Geha RS, Bonilla FA. Acute chylothorax in children: selective retention of memory T cells and natural killer cells. J Pediatr 2003; 143:243.</a></li><li><a class="nounderline abstract_t">Hoskote AU, Ramaiah RN, Cale CM, et al. Role of immunoglobulin supplementation for secondary immunodeficiency associated with chylothorax after pediatric cardiothoracic surgery. Pediatr Crit Care Med 2012; 13:535.</a></li><li><a class="nounderline abstract_t">McGregor DD, Gowans JL. THE ANTIBODY RESPONSE OF RATS DEPLETED OF LYMPHOCYTES BY CHRONIC DRAINAGE FROM THE THORACIC DUCT. J Exp Med 1963; 117:303.</a></li><li><a class="nounderline abstract_t">Jolliff CR, Cost KM, Stivrins PC, et al. Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. Clin Chem 1982; 28:126.</a></li><li><a class="nounderline abstract_t">Cannizzaro V, Frey B, Bernet-Buettiker V. The role of somatostatin in the treatment of persistent chylothorax in children. Eur J Cardiothorac Surg 2006; 30:49.</a></li><li><a class="nounderline abstract_t">Shih YT, Su PH, Chen JY, et al. Common etiologies of neonatal pleural effusion. Pediatr Neonatol 2011; 52:251.</a></li><li><a class="nounderline abstract_t">Chan GM, Lechtenberg E. The use of fat-free human milk in infants with chylous pleural effusion. J Perinatol 2007; 27:434.</a></li><li><a class="nounderline abstract_t">Caserío S, Gallego C, Martin P, et al. Congenital chylothorax: from foetal life to adolescence. Acta Paediatr 2010; 99:1571.</a></li><li><a class="nounderline abstract_t">Fernández Alvarez JR, Kalache KD, Graŭel EL. Management of spontaneous congenital chylothorax: oral medium-chain triglycerides versus total parenteral nutrition. Am J Perinatol 1999; 16:415.</a></li><li><a class="nounderline abstract_t">Bellini C, Cabano R, De Angelis LC, et al. Octreotide for congenital and acquired chylothorax in newborns: A systematic review. J Paediatr Child Health 2018; 54:840.</a></li><li><a class="nounderline abstract_t">Horvers M, Mooij CF, Antonius TA. Is octreotide treatment useful in patients with congenital chylothorax? Neonatology 2012; 101:225.</a></li><li><a class="nounderline abstract_t">Arevalo RP, Bullabh P, Krauss AN, et al. Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates. J Pediatr Surg 2003; 38:251.</a></li><li><a class="nounderline abstract_t">Mohseni-Bod H, Macrae D, Slavik Z. Somatostatin analog (octreotide) in management of neonatal postoperative chylothorax: is it safe? Pediatr Crit Care Med 2004; 5:356.</a></li><li><a class="nounderline abstract_t">Reck-Burneo CA, Parekh A, Velcek FT. Is octreotide a risk factor in necrotizing enterocolitis? J Pediatr Surg 2008; 43:1209.</a></li><li><a class="nounderline abstract_t">Laje P, Halaby L, Adzick NS, Stanley CA. Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. Pediatr Diabetes 2010; 11:142.</a></li><li><a class="nounderline abstract_t">Radetti G, Gentili L, Paganini C, Messner H. Cholelithiasis in a newborn following treatment with the somatostatin analogue octreotide. Eur J Pediatr 2000; 159:550.</a></li><li><a class="nounderline abstract_t">Resch B, Sever Yildiz G, Reiterer F. Congenital Chylothorax of the Newborn: A Systematic Analysis of Published Cases between 1990 and 2018. Respiration 2022; 101:84.</a></li><li><a class="nounderline abstract_t">Bui A, Long CJ, Breitzka RL, Wolovits JS. Evaluating the Use of Octreotide for Acquired Chylothorax in Pediatric Critically Ill Patients Following Cardiac Surgery. J Pediatr Pharmacol Ther 2019; 24:406.</a></li><li><a class="nounderline abstract_t">Kugelman A, Gonen R, Bader D. Potential role of high-frequency ventilation in the treatment of severe congenital pleural effusion. Pediatr Pulmonol 2000; 29:404.</a></li><li><a class="nounderline abstract_t">Ragosta KG, Alfieris G. Chylothorax: a novel therapy. Crit Care Med 2000; 28:1208.</a></li><li><a class="nounderline abstract_t">Berkenbosch JW, Withington DE. Management of postoperative chylothorax with nitric oxide: a case report. Crit Care Med 1999; 27:1022.</a></li><li><a class="nounderline abstract_t">Muniz G, Hidalgo-Campos J, Valdivia-Tapia MDC, et al. Successful Management of Chylothorax With Etilefrine: Case Report in 2 Pediatric Patients. Pediatrics 2018; 141.</a></li><li><a class="nounderline abstract_t">Sersar SI. Predictors of prolonged drainage of chylothorax after cardiac surgery: single centre study. Pediatr Surg Int 2011; 27:811.</a></li><li><a class="nounderline abstract_t">Thorlacius EM, Mellander M, Synnergren M, Kokinsky E. Late eosinophilic pleural effusion after cardiac surgery in a neonate--prompt response to corticosteroid therapy. Paediatr Anaesth 2009; 19:633.</a></li><li><a class="nounderline abstract_t">Liviskie CJ, Brennan CC, McPherson CC, Vesoulis ZA. Propranolol for the Treatment of Lymphatic Malformations in a Neonate - A Case Report and Review of Literature. J Pediatr Pharmacol Ther 2020; 25:155.</a></li><li><a class="nounderline abstract_t">Mitchell K, Weiner A, Ramsay P, Sahni M. Use of Propranolol in the Treatment of Chylous Effusions in Infants. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Poralla C, Specht S, Born M, et al. Treatment of congenital generalized lymphangiectasia with propranolol in a preterm infant. Pediatrics 2014; 133:e439.</a></li><li><a class="nounderline abstract_t">Handal-Orefice R, Midura D, Wu JK, et al. Propranolol Therapy for Congenital Chylothorax. Pediatrics 2023; 151.</a></li><li><a class="nounderline abstract_t">Malleske DT, Yoder BA. Congenital chylothorax treated with oral sildenafil: a case report and review of the literature. J Perinatol 2015; 35:384.</a></li><li><a class="nounderline abstract_t">Law MA, McMahon WS, Hock KM, et al. Balloon Angioplasty for the Treatment of Left Innominate Vein Obstruction Related Chylothorax after Congenital Heart Surgery. Congenit Heart Dis 2015; 10:E155.</a></li><li><a class="nounderline abstract_t">McMullan DM. Should intravenous immunoglobulin be given to patients with postoperative chylothorax?. Pediatr Crit Care Med 2012; 13:599.</a></li></ol></div><div id="topicVersionRevision">Topic 87663 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16928976" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Percutaneous thoracic drainage in neonates: catheter drainage versus treatment with aspiration alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8010794" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Use of video-assisted thoracic surgery in the treatment of chylothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14602705" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Congenital idiopathic chylothorax in neonates: chemical pleurodesis with povidone-iodine (Betadine).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20140768" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Congenital chylothorax--successful management with chemical pleurodesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16492955" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Congenital chylothorax: what is the best strategy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25969129" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pleurodesis with povidone-iodine for refractory chylothorax in newborns: Personal experience and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17594205" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Dosage and effectiveness of intrapleural doxycycline for pediatric postcardiotomy pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12556936" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fibrin glue for persistent pneumothorax in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19381502" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Successful treatment of congenital chylothorax using fibrin glue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14618523" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Successful management of severe chylothorax with argon plasma fulguration and fibrin glue in a premature infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8156471" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Successful management of postoperative chylothorax with fibrin glue in a premature neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6189249" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment of postsurgical chylothorax with fibrin glue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19302856" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Massive chylothorax in small babies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32879418" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Neonatal lymphatic flow disorders: impact of lymphatic imaging and interventions on outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19302843" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment with OK-432 for persistent congenital chylothorax in newborn infants resistant to octreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20665432" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Postoperative chylothorax in congenital diaphragmatic hernia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20597075" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Novel surgical technique for insertion of pleuroperitoneal shunts for bilateral chylous effusions in Ex preterm infant at term corrected age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10052806" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The use of pleuroperitoneal shunts in the management of persistent chylothorax in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728246" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pleuroperitoneal shunts for refractory chylothorax after operation for congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21144029" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chylothorax after surgery on congenital heart disease in newborns and infants -risk factors and efficacy of MCT-diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10802499" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Etiology and management of pediatric chylothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062221" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chylothorax in children after congenital heart surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/377645" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Thoracic duct drainage in organ transplantation: will it permit better immunosuppression?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13655215" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The recirculation of lymphocytes from blood to lymph in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25480460" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Congenital chylothorax: a prospective nationwide epidemiological study in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28342580" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Evidence-based management of chylothorax in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10712723" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Use of intravenous immunoglobulins as an adjunct in the conservative management of chylothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970641" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Acute chylothorax in children: selective retention of memory T cells and natural killer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22760424" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Role of immunoglobulin supplementation for secondary immunodeficiency associated with chylothorax after pediatric cardiothoracic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19867225" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : THE ANTIBODY RESPONSE OF RATS DEPLETED OF LYMPHOCYTES BY CHRONIC DRAINAGE FROM THE THORACIC DUCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7055895" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16725334" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The role of somatostatin in the treatment of persistent chylothorax in children</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22036219" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Common etiologies of neonatal pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17554391" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The use of fat-free human milk in infants with chylous pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20528795" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Congenital chylothorax: from foetal life to adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10772201" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Management of spontaneous congenital chylothorax: oral medium-chain triglycerides versus total parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29602276" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Octreotide for congenital and acquired chylothorax in newborns: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22076538" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Is octreotide treatment useful in patients with congenital chylothorax?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12596116" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215005" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Somatostatin analog (octreotide) in management of neonatal postoperative chylothorax: is it safe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18558210" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Is octreotide a risk factor in necrotizing enterocolitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19558634" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10923237" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cholelithiasis in a newborn following treatment with the somatostatin analogue octreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34515211" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Congenital Chylothorax of the Newborn: A Systematic Analysis of Published Cases between 1990 and 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31598104" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evaluating the Use of Octreotide for Acquired Chylothorax in Pediatric Critically Ill Patients Following Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10790254" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Potential role of high-frequency ventilation in the treatment of severe congenital pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10809307" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Chylothorax: a novel therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10362431" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Management of postoperative chylothorax with nitric oxide: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29703801" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Successful Management of Chylothorax With Etilefrine: Case Report in 2 Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21660449" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Predictors of prolonged drainage of chylothorax after cardiac surgery: single centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19645993" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Late eosinophilic pleural effusion after cardiac surgery in a neonate--prompt response to corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32071591" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Propranolol for the Treatment of Lymphatic Malformations in a Neonate - A Case Report and Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34187907" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Use of Propranolol in the Treatment of Chylous Effusions in Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24446440" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of congenital generalized lymphangiectasia with propranolol in a preterm infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36651059" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Propranolol Therapy for Congenital Chylothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25917021" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Congenital chylothorax treated with oral sildenafil: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25600286" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Balloon Angioplasty for the Treatment of Left Innominate Vein Obstruction Related Chylothorax after Congenital Heart Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22955461" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Should intravenous immunoglobulin be given to patients with postoperative chylothorax?.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
